In Vivo's 2016 Deals Of The Year: The Winners Are…
We nominated 15 deals in three categories. You picked the winners. (Free article.)
Top Alliance: AstraZeneca's Asset Drop
- 38% of you picked AstraZeneca PLC's year-long purge of non-core assets, which climaxed in October with five out-licensing deals cumulatively worth more than $1 billion. Casebia Therapeutics, Bayer AG's JV with CRISPR Therapeutics AG, was runner-up with 26% of the vote.
Top Financing: It's A Tie!
- 40% of you voted for the $474 million equity financing that mRNA drug developer Moderna Therapeutics LLC closed in September. And 40% voted for Samsung BioLogics'$2 billion IPO –a big validation for biologics development in South Korea and also a demonstration of the importance of diversification for parent Samsung.
Top M&A: QuintilesIMS: Big Merger In Big Data